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Abstract
Background: This study was aimed 1) to investigate the predictive value of FDG PET/CT (fluorine-18
fluorodeoxyglucose positron emission tomography/computed tomography) for histopathologic response and 2) to
explore the results of FDG PET/CT by molecular phenotypes of breast cancer patients who received neoadjuvant
chemotherapy.
Methods: Seventy-eight stage II or III breast cancer patients who received neoadjuvant docetaxel/doxorubicin
chemotherapy were enrolled in this study. FDG PET/CTs were acquired before chemotherapy and after the first
cycle of chemotherapy for evaluating early metabolic response.
Results: The mean pre- and post-chemotherapy standard uptake value (SUV) were 7.5 and 3.9, respectively. The
early metabolic response provided by FDG PET/CT after one cycle of neoadjuvant chemotherapy was correlated
with the histopathologic response after completion of neoadjuvant chemotherapy (P = 0.002). Sensitivity and
negative predictive value were 85.7% and 95.1%, respectively. The estrogen receptor negative phenotype had a
higher pre-chemotherapy SUV (8.6 vs. 6.4, P=0.047) and percent change in SUV (48% vs. 30%, P=0.038). In triple
negative breast cancer (TNBC), the pre-chemotherapy SUV was higher than in non-TNBC (9.8 vs. 6.4, P=0.008).
Conclusions: The early metabolic response using FDG PET/CT could have a predictive value for the assessment of
histopathologic non-response of stage II/III breast cancer treated with neoadjuvant chemotherapy. Our findings
suggest that the initial SUV and the decline in SUV differed based on the molecular phenotype.
Trial Registration: ClinicalTrials.gov: NCT01396655
Keywords: FDG PET, breast cancer, neoadjuvant chemotherapy, molecular phenotype
Background
Breast cancer is second most common cancer in Korean
women [1]. Neoadjuvant chemotherapy, also called preo-
perative chemotherapy, has emerged as the preferred
initial component of therapy for patients diagnosed with
locally advanced breast cancer. In the treatment of locally
advanced breast cancer, multimodality approach, including
neoadjuvant chemotherapy, surgery, and radiotherapy, is
needed [2-4].
Over the last decade, the clinical value of fluorine-18
fluorodeoxyglucose positron emission tomography (FDG
PET) in breast cancer has been widely studied [5-8]. How-
ever, a few studies have been conducted in stage II or III
breast cancer patients receiving neoadjuvant chemother-
apy, and the role of FDG PET remains inconclusive
because of the small number of patients and heteroge-
neous regimens [9-13].
Furthermore, breast cancer is a heterogeneous disease
with a demonstrated difference in prognosis based on
molecular phenotypes. Many researchers have attempted
to perform risk stratification and individualized treat-
ment according to molecular phenotypes. We conducted
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doxorubicin chemotherapy in stage II or III breast cancer
and recently reported the prognostic and predictive role
of the molecular markers [14,15].
However, little is known how we consider the molecu-
lar phenotypes of breast cancer in order to interpret FDG
PET findings [16]. This lead us to further investigate
FDG PET in stage II or III breast cancer patients who
received neoadjuvant chemotherapy, and FDG PET/CT
was performed as a part of large clinical phase II study.
The objectives of this study were 1) to investigate the
predictive value of FDG PET/CT for histopathologic
responses and 2) to explore the results of FDG PET/CT
by molecular phenotypes of breast cancer.
Methods
Patients and treatment
Between July 2006 and September 2008, a total of 78 stage
II or III breast cancer patients who received neoadjuvant
docetaxel/doxorubicin chemotherapy were enrolled in this
prospective study. The primary endpoint of this trial was
evaluating pathologic complete response (pCR) rate,
because pCR is repeatedly confirmed most relievable prog-
nostic factor for neoadjuvant chemotherapy [17,18], and
the best predictor of improved outcome and prolonged
survival [3]. Secondary endpoints were evaluating survival,
toxicity, predictive factors, and early metabolic response.
The eligibility criteria were described in our prior reports
[14,15]. In brief, the eligibility criteria were as follows: 1)
pathologically-confirmed breast cancer by core needle
biopsy, 2) initial clinical stage II or III, 3) objective measur-
able lesion, 4) ECOG performance 0~2, 5) previously
untreated, and 6) adequate bone marrow, hepatic, cardiac,
and renal functions. The patients received three cycles of
neoadjuvant docetaxel/doxorubicin chemotherapy. The
chemotherapeutic regimen consisted of docetaxel (75 mg/
m
2) and doxorubicin (50 mg/m
2) by intravenous infusion
every 3 weeks. After three cycles of neoadjuvant che-
motherapy, the patients were re-evaluated for response
and underwent curative surgery. Radiologic response was
evaluated using breast magnetic resonance imaging (MRI)
for the primary breast tumor and chest computed tomo-
graphy (CT) for axillary, supraclavicular, internal mam-
mary lymph nodes with RECIST criteria [19]. Both breast
MRI and chest CT were performed in all the 78 patients.
Subsequently, the patients received three more cycles of
docetaxel and doxorubicin as an adjuvant chemotherapy,
followed by hormonal or radiation therapy, if indicated
[20]. Figure 1 shows the scheme for this study protocol.
This regimen is known to be effective as neoadjuvant che-
motherapy for stage II or III breast cancer [14,15,21]. We
performed retrospective descriptive analysis for PET/CTs
within this prospective study. This study protocol was
conducted under the approval of the Institutional Review
Board of Seoul National University Hospital (IRB approval
number: 0510-506-159).
Pathologic Assessment
The molecular markers that we have examined included
estrogen receptor (ER), progesterone receptor (PR),
human epidermal growth factor receptor 2 (HER2), and
Ki-67. We performed immunohistochemistry (IHC) using
tissues obtained before treatment and evaluated the asso-
ciation with clinical outcomes. IHC was performed as pre-
viously described [15,22]. The cut-off for ER and PR
positivity was ≥ 10% positive tumor cells with nuclear
staining. HER2 positivity was defined as either HER2 gene
amplification by fluorescent in situ hybridization or scored
as 3+ by IHC [23]. The molecular phenotypes of breast
cancer were classified into luminal A, luminal B, HER2
and triple negative breast cancer (TNBC) [24]. TNBC was
defined as ER(-), PR(-), and HER2(-). Luminal A pheno-
type was defined as ER(+) or PR(+) and HER2(-) tumor,
and luminal B phenotype was defined as ER(+) or PR(+)
and HER2(+). ER(-) and PR (-) and HER2+ tumor was
classified as HER2 phenotype. Low expression of Ki-67
was defined as ≤5%. Histopathologic response was classi-
fied as proposed by Honkoop et al. [25] Specimens with
no residual invasive carcinoma were classified as pCR.
Residual ductal carcinoma in situ was included in the pCR
category [26]. Specimens with only few scattered foci of
microscopic residual invasive tumor were classified as
minimal residual disease (MRD). Gross residual disease
(GRD) comprised tumors showing macroscopic residual
tumor or extensive residual tumor infiltration on micro-
scopic examination. pCR and MRD were defined as histo-
pathologic response and GRD as no histopathologic
response.
FDG PET/CT studies
Whole-body fluorine-18 FDG PET/CT scans were
acquired before and after neoadjuvant chemotherapy for
early metabolic response prediction. On the 15
th day of
the first cycle of neoadjuvant chemotherapy, we obtained
follow-up whole-body fluorine-18 FDG PET/CT scans.
The CT scan protocol was as follows: tube voltage, 120
kV; current intensity, 50 mAs; scan time, 43.2 seconds;
effective radiation dose, 4.8 mSv. FDG PET/CT was done
using the same scanner (Gemini PET/CT system; Philips,
Milpitas, CA, USA). Patients fasted for at least 6 hours
before fluorine-18 FDG was injected intravenously.
Patients were administered a weight-adjusted dosed of
fluorine-18 FDG (5.18 MBq/kg), and images were
acquired approximately 60 minutes (range: 50-75 min-
utes) after an intravenous injection of fluorine-18 FDG.
Whole body emission scans were obtained for 2 minutes
per bed position. PET/CT scanners automatically calcu-
lated the decay-corrected injected activity. We flushed
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activities in the syringe were less than 20 μCi and negligi-
ble. All patients were studied in the supine position with
both arms raised above the head to pull their breast away.
Attenuation correction was based on the CT data, and
PET data reconstruction was done by a 3-dimensional
row action maximum likelihood algorithm. For quantita-
tive assessment of tumor FDG uptake, region of interest
were manually drawn on the slice with the highest
radioactivity concentration of the primary breast tumor
and in the adjacent slices.
The standard uptake values (SUVs) were calculated from
the amount of FDG injected, body weight, and soft tissue
uptake in the attenuation-corrected regional images as fol-
lows: SUV = (activity/unit volume)/(injected dose/body
weight). Maximal SUV was defined as the SUV value on
one pixel with the highest counts within the region of
interest. The lesion chosen for analysis was the primary
breast lesion with the highest SUV. The pre-treatment
baseline maximal SUV of the tumor (pre-SUV) and the
SUV of the tumor after the first cycle of chemotherapy
(post-SUV) were compared with clinico-pathologic para-
meters. Calculation of the uptake index was as follows:
ΔSUV% = 100 × (pre-SUV - post-SUV)/pre-SUV.
Statistical analysis
This is a subproject of a phase II trial. The primary end-
point of the main project was pCR, and we designed this
trial to test null hypothesis that the pCR rate was at most
10% against the alternative hypothesis that it was at least
20%. A sample size of 78 patients provided 80% power to
test this hypothesis and a 0.05, using Simon’st w os t a g e
minimax design [27]. The statistical consideration was
performed according to the main project. The subproject
has investigated the early metabolic change as primary
endpoint. This was an exploratory analysis only, without
an own sample size calculation for subproject. The pri-
mary objective of this subproject was to find a correlation
between early metabolic response and pathological
response. The association between histopathologic and
metabolic response were assessed by a chi-square test.
The cut-off of the SUV change for metabolic response was
not prospectively defined. Receiver-operating characteris-
tics (ROC) analysis was performed to determine a thresh-
old for the prediction of metabolic response. The Mann-
Whitney U test or Kruskal-Wallis test were used to com-
pare SUVs according to different molecular phenotypes.
All statistical tests were two-sided, with the level of signifi-
cance established at P < 0.05. SPSS software (SPSS, Inc.,
Chicago, IL, USA) was used for all statistical analyses.
Results
Patients and results of treatment
The pretreatment characteristics are given in Table 1.
Twelve patients (15.7%) were initially staged clinical stage
II and the others (84.3%) were initial staged clinical stage
III. The median follow-up duration was 18.7 months
(range, 4.9-30.9 months). The tumor size was a median
of 4.5 cm in the greatest dimension (range, 2.0-11.0 cm).
At the end of follow-up, eight patients had developed
recurrent disease, and one patient had died. The overall
histopathologic response rate was 17.9%. Table 2 shows
the results to neoadjuvant chemotherapy.
Changes in FDG PET/CT during neoadjuvant
chemotherapy
The mean maximal SUVs ± standard deviation (SD)
were as follows: pre-SUV = 7.5 ± 4.3 (range, 1.4~22.1),
Figure 1 Schematic flow of the neoadjuvant chemotherapy and response assessed by FDG PET/CT, breast MRI and chest CT.
Abbreviations: DD, docetaxel+doxorubicin; FDG PET, fluorine-18 fluorodeoxyglucose positron emission tomography; CT, computed tomography;
MRI, magnetic resonance imaging; USG, ultrasonography.
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40% (range, -260%~100%; SD = 46). The treatment
response was assessed by breast MRI and chest CT for
radiologic response and by FDG PET/CT for early meta-
bolic response. Δ SUV% and decrease % of tumor dia-
meter measured by RECIST criteria were well correlated
(Pearson correlation coefficient = 0.267, P = 0.019).
ROC analysis were performed to determine optimal
cut-off values of Δ SUV% to differentiate metabolic
responder and non-responder, based on histopathologic
response (Figure 2). The cut-off to achieve the highest
positive predictive value was Δ SUV% of 50% (sensitivity
of 85.7%, specificity of 60.9%). Among the all 78 patients,
37 patients (47.4%) achieved metabolic response, while
41 patients (52.6%) did not.
Δ SUV% was significantly greater in patients with his-
topathologic response than patients without histopatho-
logic response (63% vs. 34%, P = 0.001, Table 3). Pre-
SUVs were not different between histopathologic
responder and non-responder, however post-SUVs were
significantly differed, and this led to a difference of Δ
SUV%. Histopathologic response was higher in early
metabolic responders determined by FDG PET/CT after
one cycle of neoadjuvant chemotherapy (P = 0.002)
(Table 4). Among 14 histopathologic responder, 12
( 8 5 . 7 % )s h o w e dm e t a b o l i cr e s p o n s e .I m p o r t a n t l y ,3 9
patients among the 41 metabolic non-responders
(95.1%) were eventually revealed as histopathologic non-
responder (Table 4).
Changes in FDG PET/CT and histopathologic response
according to molecular phenotype
The FDG PET/CT results were different according to
the molecular phenotype of the breast cancer. The ER
Table 1 Baseline characteristics of 78 patients
Characteristics No. of Pt (%)
Median age (range) 45 (range 29-69)
Age < 50 56 (71.8)
Age ≥50 22 (28.2)
Performance status
ECOG 0 23 (29.5)
ECOG 1 55 (70.5)
Pathologic characteristics
Invasive ductal carcinoma 74 (94.9)
Others 4 (5.1)
Initial clinical stage
IIA 1 (1.3)
IIB 11 (14.1)
IIIA 47 (60.3)
IIIB 13 (16.7)
IIIC 6 (7.7)
Inflammatory breast cancer
Yes 3 (3.8)
No 75 (96.2)
Type of surgery
Breast conserving 44 (56.4)
Mastectomy 34 (43.6)
Adjuvant hormonal therapy
Yes 52 (66.7)
No 26 (33.3)
Adjuvant radiation therapy
Yes 66 (84.6)
No 12 (15.4)
ECOG, Eastern Cooperative Oncology Group.
Table 2 Results to docetaxel plus doxorubicin
neoadjuvant chemotherapy
Response No. of Pts (%)
Histopathologic response
Pathologic complete response 4 (5.1)
Minimal residual disease 10 (12.8)
Gross residual disease 64 (82.1)
Figure 2 Receiver-operating characteristics (ROC) analysis,
determine optimal cut-off values of ΔSUV%; Area under the
curve ROC was 0.79 (95% confidence interval 0.64-0.93).
Table 3 Correlation between response and SUV values.
Response Pre-SUV Post-SUV ΔSUV%
Histopathologic response
Responders 7.3 ± 4.2 2.2 ± 1.9 63 ± 48
Non-responders 7.6 ± 4.4 4.3 ± 2.7 34 ± 47
P = 0.795 P = 0.004 P = 0.001
SUV, standard uptake value
P-value based on the Mann-Whitney U test, presuming to be non-parametric
statistics
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6.4, P=0.047) and Δ SUV% (48% vs. 30%, P=0.038)
than ER positive phenotype. In patients with high Ki-67
expression, a similar phenomenon was observed in that
the pre-SUV and Δ SUV% were higher than in the low
Ki-67 expression group (8.5 vs.6 . 2 ,P=0.018; 49% vs.
27%, P=0.052, respectively). In the TNBC group, the
pre-chemotherapy SUV was higher than in the non-
TNBC group (9.8 vs.6 . 4 ,P=0.008); however, the Δ
SUV% was not different (P=0.799). Table 5 and Figure
3 show the serial FDG PET/CT results according to
molecular phenotypes. Histopathologic response rate
was higher in ER negative patients than ER positive
patients (27.5% vs.7 . 9 % ,P = 0.037) and early metabolic
response rate tend to higher in ER negative patients
(57.5% vs. 36.8%, P = 0.068). In this context, histopatho-
logic response rate was significantly different according
to molecular phenotype (P = 0.018) and metabolic
response tend to higher in HER2+ and TNBC subtypes
than luminal type (66.7% vs. 50.0% vs. 40.0%, P = 0.255).
Sensitivity and specificity of metabolic response for his-
topathologic response were higher in ER positive pheno-
type (100.0% and 68.6%, respectively) than those of ER
negative phenotype (81.8% and 51.7%, respectively).
Discussion
In the present study, we found that the early metabolic
response using serial FDG PET/CT had a high predictive
value for the histopathologic non-response of stage II/III
breast cancer treated with neoadjuvant chemotherapy.
Our study has demonstrated that the early metabolic
response obtained on the 15
th day of first cycle of neoad-
juvant chemotherapy may be useful in determining histo-
pathologic non-responders with high negative predictive
value of 95.1%, however, its value to identify histopatho-
logic responders was low with positive predictive value of
32.4%. Different molecular phenotypes based on IHC
reflect different metabolic properties and different histo-
pathologic response rate.
Because current methods to monitoring tumor
response (i.e., physical examination and conventional
imaging modalities) have potential limitations [12], early
metabolic responses by serial FDG PET/CT would be a
useful complementary tool. Assessment of therapeutic
response with serial FDG PET/CT scans was possible
earlier than with any other method. Early evaluation of
chemosensitivity in vivo using serial FDG PET/CT would
help to identify non-responding patients, to avoid ineffec-
tive chemotherapy [28,29] and to decide the most appro-
priate therapeutic strategy. With given sensitivity of
85.7% and negative predictive value of 95.1%, metabolic
non-responders identified by early serial FDG PET/CTs
were likely to be histopathologic non-responders. In
order to improve treatment outcome by risk stratifica-
tion, the metabolic non-responder could be considered
to have received another treatment strategy in earlier
time course. It is necessary to design a future prospective
randomized clinical trial comparing continuing standard
cytotoxic chemotherapy alone versus incorporating new
agents for metabolic non-responders to decide the clini-
cal value of early determination of metabolic non-
response.
Our study confirms previous reports [9,10,12,13,29-36]
on the predictive value of changes in glucose metabolism
after neoadjuvant chemotherapy in a prospective setting.
Rousseau et al. [12] reported sensitivity of 61%, specificity
of 96%, and negative predictive value of 68% when using
FDG PET/CT after the first cycle of chemotherapy with a
SUV cut-off of 60%. When comparing PET/CTs obtained
baseline and 2nd cycles of chemotherapy, sensitivity and
specificity were reported 73% and 63% with a cut-off of
45% [35], 93% and 75% with a cut-off of 50% [29], 77%
and 80% with a cut-off of 40% [31]. The previous studies
using FDG PET in neoadjuvant settings have indicated
that measurements of SUV or changes in SUV during
neoadjuvant chemotherapy allow prediction of histo-
pathologic response as well as survival [9,10,12,13,29-37].
We used Δ S U V %b e c a u s ei tw a sf o u n dt ob et h eo n l y
Table 4 Correlation between metabolic, and histopathologic response.
Response Histopathologic responders * Histopathologic
non-responders
P-value
†
Metabolic responders
Responders 12 (32.4%) 25 (67.6%) 0.002
Non-responders 2 (4.9%) 39 (95.1%)
For histopathologic responders For histopathologic nonresponder
Sensitivity 85.7% (12/14) 60.9% (39/64)
Specificity 60.9% (39/64) 85.7% (12/14)
Positive predictive value 32.4% (12/37) 95.1% (39/41)
Negative predictive value 95.1% (39/41) 32.4% (12/37)
* Pathologic complete response or minimal residual disease were regarded as histopathologic responders, Gross residual disease were regarded as
histopathologic non-responders.
† P-value based on the Fisher’s exact test
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in previous report [30]. Histopathologic response was
higher in metabolic responder compared with metabolic
non-responder (32.4% vs. 4.9%) although substantial por-
tion of metabolic responder did not eventually get histo-
pathologic response. Lower histopathologic response rate
in our study was attributed to relatively short course of
neoadjuvant chemotherapy in relatively advanced large
tumors (median tumor size 4.5 cm). Importantly, 39 out
of 41 metabolic non-responders did not get pathologic
response which makes high negative predictive value
(95.1%), and 85.7% of metabolic responders eventually
showed pathologic response.
Bos et al. [16] reported that
18FDG uptake in breast
cancer was determined by the several biologic markers
including glucose transporter-1, hexokinase I expression
and mitotic activity index in breast cancer. Avril et al.
[38] analyzed 56 operable breast cancer patients, and
reported the positive correlation between baseline FDG
uptake and tumor cell proliferation, which were similar
with our results. In that report, hormone receptor nega-
tive breast cancer tended to have higher pre-SUV level
than hormone receptor positive breast cancer, even
though not reached statistical significance. However, little
is currently known about the correlation between the
SUV changes of FDG PET results and the meaning of
molecular phenotype which is commonly used in the
clinic to decide the treatment plan. In our study, breast
cancer patients with high expression of Ki-67, which is
regarded as highly proliferative and aggressive [39],
showed a higher pre-SUV. ER negativity and high expres-
sion of Ki-67 was also associated with a high declining of
the SUV. The pre-chemotherapy SUV of TNBC was
higher than in non-TNBC, which was in line with other
study [40].
Our study has some limitation. First, the median fol-
low-up duration is relatively short with median follow-up
duration of 18.7 months. As only few patients experi-
enced relapses, we did not make an attempt to correlate
the results of FDG PET/CT with survival. Second, the
Table 5 SUV and changes in SUV based on molecular phenotypes
No. of Pts Pre-SUV * Post-SUV * ΔSUV% * HPR (%)
ER
Positive 38 6.4 ± 3.3 3.7 ± 2.1 30 ± 57 3 (7.9)
Negative 40 8.6 ± 4.9 4.1 ± 3.1 48 ± 37 11 (27.5)
P = 0.047 P = 0.936 P = 0.038 P = 0.037
†
PR
Positive 30 6.5 ± 3.3 3.5 ± 2.4 36 ± 63 3 (10.0)
Negative 48 8.2 ± 4.8 4.2 ± 2.8 42 ± 37 11 (22.9)
P = 0.187 P = 0.347 P = 0.837 P = 0.226
†
HER2
Positive 17 6.8 ± 3.2 3.2 ± 2.6 51 ± 36 5 (29.4%)
Negative 61 7.7 ± 4.6 4.1 ± 2.7 36 ± 51 9 (14.8%)
P = 0.818 P = 0.247 P = 0.189 P = 0.164
†
Triple negativity
TNBC 26 9.8 ± 5.3 5.0 ± 3.0 42 ± 35 6 (23.1)
Non-TNBC 52 6.4 ± 3.2 3.4 ± 2.3 38 ± 54 8 (15.4)
P = 0.008 P = 0.076 P = 0.799 P = 0.404
†
Molecular phenotype
Luminal A/B 40 6.3 ± 3.3 3.6 ± 2.2 33 ± 57 3 (7.5)
HER2 12 6.6 ± 3.2 2.8 ± 2.6 56 ± 39 5 (41.7)
TNBC 26 9.8 ± 5.3 5.0 ± 3.0 42 ± 35 6 (23.1)
P = 0.016
‡ P = 0.055
‡ P = 0.150
‡ P = 0.018
†
Ki-67
Low expression
§ 30 6.2 ± 4.1 3.6 ± 2.6 27 ± 65 4 (13.3)
High expression 41 8.5 ± 4.4 4.0 ± 2.8 49 ± 33 10 (24.4)
P = 0.018 P = 0.541 P = 0.052 P = 0.367
†
HPR, histopathologic responder; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast
cancer.
* Data are presented as the mean ± standard deviation.
† P-values are based on Chi square or Fisher’s exact test.
‡ P-values are based on Kruskal-Wallis test, otherwise P-values are based on Mann-Whitney U test, presuming to be non-parametric statistics.
§ Low expression of Ki-67 was defined as ≤ 5%, and 7 patients were not available for Ki-67 results.
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negative phenotype showed higher pre-SUV (A) and Δ SUV% (B) than ER positive phenotype. In patients with high Ki-67 expression, a similar
phenomenon was observed in that pre-SUV (C) and Δ SUV% (D) was higher than the low Ki-67 expression group. In triple negative breast cancer
(TNBC), pre-SUV (E) was higher than non-TNBC; however, Δ SUV% (F) was not different.
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study. Third, we did not obtain confirmatory statistical
power for subgroup analysis.
However, our study was the first study exploring the
metabolic uptake changes according to the clinically rele-
vant molecular phenotype using serial FDG PET/CT
before and after neoadjuvant chemotherapy. The patient
population was highly homogenous in terms of stage and
treated by same chemotherapy regimen and schedule.
SUVs were obtained by the same PET/CT machine with
the same protocol in a single institution. Metabolic lesions
were well-matched because we used a combined PET/CT
system.
Conclusions
Despite some limitations, this study suggests that early
metabolic response assessment with FDG PET/CT after
the first cycle of neoadjuvant chemotherapy accuratly
predicted histopathologic non-response and could be
useful to identify patients undergoing ineffective or
needing more aggressive chemotherapy. We also
observed that the initial SUV and declining of the SUV
differed based on molecular phenotype. Further prospec-
tive studies confirming the retrospectively calculated
cut-off of 50%, and using longer duration of neoadjuvant
chemotherapy with serial FDG PET/CT including early
time point and just prior to definitive surgery are
warranted.
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